ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bearishXiaomi Corp
26 Nov 2023 06:17

HK Connect SOUTHBOUND Flows (To 24 Nov 23); ETF Buying Offsets Broad Selling, Especially in Tech

HK Connect SOUTHBOUND flows were to the sell side again. Last week was driven by ETFs, this week by single stocks, especially tech, and China...

Logo
474 Views
Share
bearishMeituan
19 Nov 2023 16:34

HK Connect SOUTHBOUND (To 17 Nov 23); High-Div SOEs Pause, Tech + ETFs Break 16wk Inflow Streak

HK Connect (SOUTHBOUND) saw its first net sell week in four months this past week, with the net sell driven by large ETF sell flows from a small...

Logo
424 Views
Share
19 Nov 2023 10:05

HK Short Interest Weekly: Kuaishou, Yum China, Hkex, Petrochina

We analyzed the latest HK SFC report for aggregate short position as of Nov 10th and highlight short interest changes in Kuaishou, Yum China, Hkex,...

Logo
451 Views
Share
bullishPasona Group
19 Nov 2023 07:05

Last Week in Event SPACE: Zhejiang, Pasona, ENN Energy, Asahi Group, Azure Minerals

The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...

Logo
484 Views
Share
x